MARKET

NTRA

NTRA

Natera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

120.16
+4.25
+3.67%
After Hours: 120.50 +0.34 +0.28% 18:35 01/15 EST
OPEN
115.93
PREV CLOSE
115.91
HIGH
122.98
LOW
115.80
VOLUME
1.05M
TURNOVER
--
52 WEEK HIGH
122.98
52 WEEK LOW
16.87
MARKET CAP
10.26B
P/E (TTM)
-50.3583
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
63.0% Return Seen to Date on SmarTrend Natera Inc Call (NTRA)
SmarTrend identified an Uptrend for Natera Inc (NASDAQ:NTRA) on November 4th, 2020 at $73.72. In approximately 2 months, Natera Inc has returned 63.00% as of today's recent price of $120.16.
Comtex SmarTrend(R) · 10h ago
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14)
Benzinga · 1d ago
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ Testing
, /PRNewswire/ --  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on the Prospera test at the American Society of Transplant Surgeons (ASTS) 21st Annual Winter Symposium, taking place .
PR Newswire - PRF · 2d ago
The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 13)
Benzinga · 2d ago
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
, /PRNewswire/ -- (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology's 2021 Gastrointestinal Cancers Symposium (ASCO GI), taking place .
PR Newswire - PRF · 4d ago
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology's 2021 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 15-17, 2021.
PR Newswire · 4d ago
Prenatal and New-born Genetic Testing Market Share, Growth, Statistics, by Application, Production, Revenue & Forecast to 2025
Jan 11, 2021 (Market Insight Reports) -- Selbyville, Delaware Prenatal and New-born Genetic Testing Market research now available at Market Study Report...
Market Insight Reports · 5d ago
Carrier Screening Market Will Grow at CAGR During Forecast Period Global Evaluation by Trends, Proportions, Share, Swot, Key Developments and Forecast till 2025
Jan 11, 2021 (Heraldkeepers) -- Market Analysis The global carrier screening market is anticipated to touch USD 4,200 million at a 16.8% CAGR between 2019-...
Heraldkeepers · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NTRA. Analyze the recent business situations of Natera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NTRA stock price target is 107.88 with a high estimate of 127.00 and a low estimate of 87.00.
EPS
Institutional Holdings
Institutions: 338
Institutional Holdings: 94.80M
% Owned: 111.04%
Shares Outstanding: 85.37M
TypeInstitutionsShares
Increased
92
6.56M
New
74
2.04M
Decreased
77
5.43M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.03%
Healthcare Equipment & Supplies
+0.12%
Key Executives
Chairman/Co-Founder/Director
Matthew Rabinowitz
President/Chief Executive Officer/Director
Steven Chapman
Co-Founder/Chief Technology Officer/Director
Jonathan Sheena
Chief Financial Officer/IR Contact Officer
Michael Brophy
Chief Operating Officer
Robert Schueren
Lead Director/Independent Director
Roelof Botha
Independent Director
Roy Baynes
Independent Director
Monica Bertagnolli
Independent Director
Rowan Chapman
Independent Director
Todd Cozzens
Independent Director
James Healy
Independent Director
Gail Marcus
Independent Director
Herman Rosenman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NTRA
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Natera Inc stock information, including NASDAQ:NTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTRA stock methods without spending real money on the virtual paper trading platform.